News & Media
|Hemostemix Amends Terms of Private Placement|
|Nov 06 2015 -
NOT FOR DISSEMINATION TO U.S. WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES
Hemostemix Inc. (“Hemostemix” or the “Company”) (TSXV: “ HEM”), a clinical-stage autologous cell-therapy company, announces it has amended the terms of its private placement offering (the “Offering”) previously announced on October 8, 2015. The Offering price has been amended to $0.65 per unit (“Unit”) and will consist of the issuance of up to 6,153,847 Units for aggregate gross proceeds of up to CDN $4,000,000.55. All other terms and conditions of the Offering shall remain the same as previously announced.
For more information, email firstname.lastname@example.org.
Neither the TSX Venture Exchange, Inc. nor its Regulation Service Provider (as that term is defined under the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
THIS PRESS RELEASE, PROVIDED PURSUANT TO APPLICABLE CANADIAN REQUIREMENTS, IS NOT FOR DISTRIBUTION TO U.S. NEWS SERVICES OR FOR DISSEMINATION IN THE UNITED STATES, AND DOES NOT CONSTITUTE AN OFFER OF THE SECURITIES DESCRIBED HEREIN. THESE SECURITIES HAVE NOT BEEN REGISTERED UNDER THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED, OR ANY STATE SECURITIES LAWS, AND MAY NOT BE OFFERED OR SOLD IN THE UNITED STATES OR TO U.S. PERSONS ABSENT REGISTRATION OR APPLICABLE EXEMPTION FROM REGISTRATION REQUIREMENTS.